1. A. Protocol:

   1. (1) Prescriptive authority for opioid antagonist drug therapy shall be exercised solely in accordance with the written protocol for opioid antagonist drug therapy approved by the board.
   2. (2) Any pharmacist exercising prescriptive authority for opioid antagonist drug therapy must maintain a current copy of the written protocol for opioid antagonist drug therapy approved by the board.

2. B. Education and training:

   1. (1) The pharmacist must successfully complete a course of training, accredited by the accreditation council for pharmacy education (ACPE), in the subject area of opioid antagonist for opioid overdose drug therapy provided by:

      1. (a) the New Mexico pharmacists association; or
      2. (b) a similar health authority or professional body approved by the board.

   2. (2) Training must include study materials and instruction in the following content areas:

      1. (a) mechanisms of action;
      2. (b) contraindications;
      3. (c) identifying indications for the use of opioid antagonist drug therapy;
      4. (d) patient screening criteria;
      5. (e) counseling and training patient and care-giver regarding the safety, efficacy and potential adverse effects of opioid antagonist;
      6. (f) evaluating patient's medical profile for drug interactions;
      7. (g) referring patient for follow-up care with primary healthcare provider;
      8. (h) informed consent;
      9. (i) record management;
      10. (j) management of adverse events.
   3. (3) Continuing education: Any pharmacist exercising prescriptive authority for opioid antagonist drug therapy shall complete a minimum of 0.1 CEU of ACPE approved opioid antagonist drug therapy related continuing education every two years.

3. C. Authorized drug(s):

   1. (1) Prescriptive authority shall be limited to opioid antagonist and shall include any device(s) approved for the administration of opioid antagonist.
   2. (2) Prescriptive authority for opioid antagonist drug therapy shall be limited to opioid antagonist as delineated in the written protocol for opioid antagonist drug therapy approved by the board.

4. D. Records:

   1. (1) The prescribing pharmacist must generate a written or electronic prescription for any opioid antagonist dispensed.
   2. (2) Informed consent must be documented in accordance with the approved protocol for opioid antagonist drug therapy and a record of such consent maintained in the pharmacy for a period of at least three years.
5. E. Notification: Upon signed consent of the patient, the pharmacist shall notify the patient's designated physician or primary care provider within 15 days of opioid antagonist dispensing.

[16.19.26.13 NMAC - N, 3/14/2014; Rn., 16.19.26.12 NMAC, 5/25/2021; A, 2/10/2026]